Antitumoral Effects of Lipids A, Clinical Studies

  • Marc BardouEmail author
  • Danièle Reisser
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 667)


Cancer remains the second leading cause of death, after cardiovascular diseases, in industrialized countries. The first goal to achieveis to prevent cancer occurrence or to diagnose it at an early and curable stage. Some screening strategies have been developed, with controversies across countries, for several cancer type; colorectal, breasts or prostate cancer for example.

Treatment of cancer is generally based on surgery and radiotherapy for localized and attainable tumors, associated, in some cases, with adjuvant chemotherapy. Chemotherapy can also be used as first line treatment for disseminated diseases.

The formulation of therapeutic strategies to enhance immune-mediated tumor destruction is a central goal of cancer immunology. Substantive progress toward delineating the mechanisms involved in innate and adaptive tumor immunity has improved the prospects for crafting efficacious treatments

LPS and their active component lipid A, have been used in tumor therapy since the 19th century.

Studies in animal models have shown promising results on different models of cancer but data from human trial are scarce. The published Phase-1 cancer studies have shown that lipid A analogues are usually well tolerated, most of the side effects being likely related to immune response, i. e., fever, chills and rigor. The administration of several lipids A analogues was shown to result in a significant increase in circulatinglevels of several cytokines but no objective antitumor responses were observed. Therefore clinical activity of such molecules deserves further experiments, likely in conjunction with chemotherapy.


Peripheral Blood Cell Biliary Tract Cancer Cancer Immunol Endotoxin Tolerance Serious Adverse Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cress RD, Morris C, Ellison GL et al. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis and race/ethnicity, 1992–2001. Cancer 2006; 107(5 Suppl):1142–1152.CrossRefPubMedGoogle Scholar
  2. 2.
    Becker N, Altenburg HP, Stegmaier C et al. Report on trends of incidence (1970–2002) of and mortality (1952–2002) from cancer in Germany. J Cancer Res Clin Oncol 2006.Google Scholar
  3. 3.
    Levi F, Lucchini F, La Vecchia C. Trends in cancer mortality in Switzerland, 1980–2001. Eur J Cancer Prev 2006; 15(1):1–9.CrossRefPubMedGoogle Scholar
  4. 4.
    West J, Wood H, Logan RF et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006; 94(11):1751–1758.CrossRefPubMedGoogle Scholar
  5. 5.
    Hoyert DL, Heron MP, Murphy SL et al. Deaths: final data for 2003. Natl Vital Stat Rep 2006; 54(13):1–120.PubMedGoogle Scholar
  6. 6.
    Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006; 24(8):1163–1177.CrossRefPubMedGoogle Scholar
  7. 7.
    Carpentier AF, Meng Y. Recent advances in immunotherapy for human glioma. CUIT Opin Oncol 2006; 18(6):631–636.CrossRefGoogle Scholar
  8. 8.
    van de Wiel PA, van der Pijl A, Bloksma N. Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity. Cancer Immunol Immunother 1991; 33(2):115–120.CrossRefPubMedGoogle Scholar
  9. 9.
    Blondiau C, Lagadec P, Lejeune P et al. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiology 1994; 190(3):243–254. 130 Lipid A in Cancer TherapyPubMedGoogle Scholar
  10. 10.
    Inagawa H, Nishizawa T, Takagi K et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res 1997; 17(3C):1961–1964.PubMedGoogle Scholar
  11. 11.
    Shimizu T, Iida K, Iwamoto Y et al. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol 1995; 17(5):425–431.CrossRefPubMedGoogle Scholar
  12. 12.
    Onier N, Lejeune P, Martin M et al. Involvement of T-lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases. Eur J Cancer 1993; 29A(14):2003–2009.CrossRefPubMedGoogle Scholar
  13. 13.
    Onier N, Hilpert S, Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999; 17(4):299–306.CrossRefPubMedGoogle Scholar
  14. 14.
    Lagadec P, Raynal S, Lieubeau B et al. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am J Pathol 1999; 154(6):1867–1876.Google Scholar
  15. 15.
    Coley WB. The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and bacillus prodigiosus. J Am Med Assoc 1898; 31:589–595.Google Scholar
  16. 16.
    Shear MJ, Turner FC. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture 61trate. J Natl Cancer Inst 1943; 4(81–97).Google Scholar
  17. 17.
    Parr I, Wheeler E, Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer 1973; 27(5):370–389.PubMedGoogle Scholar
  18. 18.
    Reisser D, Pance A, Jeannin JE Mechanisms of the antitumoral effect of lipid A. Bioessays 2002; 24:284–289.CrossRefPubMedGoogle Scholar
  19. 19.
    Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991–1045.PubMedGoogle Scholar
  20. 20.
    Verhasselt V, Buelens C, Willems F et al. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158(6):2919–2925.PubMedGoogle Scholar
  21. 21.
    Ismaili J, Rennesson J, Aksoy E et al. Monophosphoryllipid A activates both human dendritic cells and T-cells. J Immunol 2002; 168(2):926–932.PubMedGoogle Scholar
  22. 22.
    Vosika GJ, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 1984; 18(2):107–112.CrossRefPubMedGoogle Scholar
  23. 23.
    Reisser D, Arnould L, Maynadie M et al. Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients. J Endotoxin Res 1999; 5(4):189–195.Google Scholar
  24. 24.
    Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991; 51(10):2524–2530.PubMedGoogle Scholar
  25. 25.
    Mackensen A, Galanos C, Wehr U et al. Endotoxin tolerance: regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 1992; 3(6):571–579.PubMedGoogle Scholar
  26. 26.
    Mackensen A, Galanos C, Engelhardt R. Modulating activity of interferon-gamma on endotoxin-induced cytokine production in cancer patients. Blood 1991; 78(12):3254–3258.PubMedGoogle Scholar
  27. 27.
    de Bono JS, Dalgleish AG, Carmichael J et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000; 6(2):397–405.PubMedGoogle Scholar
  28. 28.
    Otto F, Schmid P, Mackensen A et al. Phase II trial of intravenous endotoxin in patients with colorectal and nonsmall cell lung cancer. Eur J Cancer 1996; 32A(10):1712–1718.CrossRefPubMedGoogle Scholar
  29. 29.
    Kiani A, Tschiersch A, Gaboriau E et al. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90(4):1673–1683.PubMedGoogle Scholar
  30. 30.
    van Deventer SJ, Buller HR, ten Care JW et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76(12):2520–2526.PubMedGoogle Scholar
  31. 31.
    Goto S, Sakai S, Kera J et al. Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Imrnunother 1996; 42(4):255–261.CrossRefGoogle Scholar
  32. 32.
    Engelhardt R, Otto F, Mackensen A et al. Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. Prog Clin Biol Res 1995; 392:253–261.PubMedGoogle Scholar
  33. 33.
    Matsuura M, Kiso M, Hasegawa A. Activity of monosaccharidelipid A analoguesin human monocytic cells as agonists or antagonists of bacterial lipopolysaccharide. Infect Immun 1999; 67(12):6286–6292.PubMedGoogle Scholar
  34. 34.
    Tarnai R, Asai Y, Hashimoto M et al. Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4. Immunology 2003; 110(1):66–72.CrossRefGoogle Scholar
  35. 35.
    Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71(5):2498–2507.CrossRefPubMedGoogle Scholar
  36. 36.
    Saha DC, Barna RS, Astiz ME et al. Monophosphoryllipid A stimulated up-regulation of reactive oxygen intermediates in human monocytes in vitro. J Leukoc Biol 2001; 70(3):381–385.PubMedGoogle Scholar
  37. 37.
    Matsumoto N, Aze Y, Akimoto A et al. ON0-4007, an antitumor lipid A analog, induces tumor necrosis factor-alpha production by human monocytes only under primed state: different effects of ONO-4007 and lipopolysaccharide on cytokine production. J Pharmacol Exp Ther 1998; 284(1):189–195.PubMedGoogle Scholar
  38. 38.
    Walzer T, Dalod M, Robbins SH et al. Natural-killer cells and dendritic cells: “l’union fait la force” Blood 2005; 106(7):2252–2258.CrossRefPubMedGoogle Scholar
  39. 39.
    Magder S, Neculcea J, Neculcea V et al. Lipopolysaccharide and TNF-alpha produce very similar changes in gene expression in human endothelial cells. J Vase Res 2006; 43(5):447–461.CrossRefGoogle Scholar
  40. 40.
    Christophi C, Winkworth A, Muralihdaran V et al. The treatment of malignancy by hyperthermia. Surg Oncol 1998; 7(1–2):83–90.CrossRefPubMedGoogle Scholar
  41. 41.
    Dinarello CA. Infection, fever and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10(4):201–222.PubMedGoogle Scholar
  42. 42.
    Engelhardt R, Mackensen A, Galanos C et al. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9(5):480–491.PubMedGoogle Scholar
  43. 43.
    Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003; 79(938):672–680.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Clinical Pharmacology Unit & Laboratory of Cardiovascular Experimental Physiology and PharmacologyFaculty of MedicineDijonFrance
  2. 2.Tumor Immunology and Immunotherapy Laboratory Inserm U866University of BurgundyDijonFrance

Personalised recommendations